3164 — Genmont Biotech Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesConservativeMicro CapFalling Star

Annual income statement for Genmont Biotech, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	428	369	318	385	401
Cost of Revenue
Gross Profit	299	257	211	238	252
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	303	307	311	345	343
Operating Profit	125	62	6.99	40.6	57.8
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	139	66.3	28.2	64.7	63.7
Provision for Income Taxes
Net Income After Taxes	110	47.5	22.4	47.8	48
Minority Interest
Net Income Before Extraordinary Items
Net Income	113	57	33	57.3	57.2
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	113	57	33	57.3	57.2
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.27	0.658	0.378	0.66	0.661
Dividends per Share